Serum microRNA liver cancer diagnostic markers and kits
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 江苏阔然生物医药科技有限公司
- Publication Date
- 2019-12-03
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of biomedical diagnosis, and in particular relates to a liver cancer diagnostic combination composed of serum microRNA, said serum microRNA including hsa-miR-145, hsa-miR-29a, hsa-miR-29c, hsa-miR-133a, hsa -miR-192 and hsa-miR-505, and a kit for the diagnosis of liver cancer and its application. Background technique
[0002] Primary liver cancer is a common malignant tumor with high morbidity and mortality worldwide, among which hepatocellular carcinoma (referred to as liver cancer, Hepatocellular Carcinoma, HCC) accounts for more than 90% of primary liver cancer. According to the "Global Cancer Report 2014" issued by the World Health Organization, in 2012, the new cases of liver cancer in the world ranked fifth among malignant tumors, and its fatality rate ranked second. Among them, the new cases and deaths of liver cancer in China were about accounted for half of the global cases. Due to the lack of effective scr...